231 related articles for article (PubMed ID: 26044541)
1. Intranasal immunization with an epitope-based vaccine results in earlier protection, but not better protective efficacy, against Helicobacter pylori compared to subcutaneous immunization.
Li H; Zhang J; He Y; Li B; Chen L; Huang W; Zou Q; Wu C
Immunol Res; 2015 Jul; 62(3):368-76. PubMed ID: 26044541
[TBL] [Abstract][Full Text] [Related]
2. Oral Immunization with a Multivalent Epitope-Based Vaccine, Based on NAP, Urease, HSP60, and HpaA, Provides Therapeutic Effect on
Guo L; Yang H; Tang F; Yin R; Liu H; Gong X; Wei J; Zhang Y; Xu G; Liu K
Front Cell Infect Microbiol; 2017; 7():349. PubMed ID: 28824883
[TBL] [Abstract][Full Text] [Related]
3. Protection against Helicobacter pylori infection following immunization is IL-12-dependent and mediated by Th1 cells.
Akhiani AA; Pappo J; Kabok Z; Schön K; Gao W; Franzén LE; Lycke N
J Immunol; 2002 Dec; 169(12):6977-84. PubMed ID: 12471132
[TBL] [Abstract][Full Text] [Related]
4. Systemic immunization with an epitope-based vaccine elicits a Th1-biased response and provides protection against Helicobacter pylori in mice.
Li HB; Zhang JY; He YF; Chen L; Li B; Liu KY; Yang WC; Zhao Z; Zou QM; Wu C
Vaccine; 2012 Dec; 31(1):120-6. PubMed ID: 23137845
[TBL] [Abstract][Full Text] [Related]
5. Immunological response of recombinant H. pylori multi-epitope vaccine with different vaccination strategies.
Wang B; Pan X; Wang H; Zhou Y; Zhu J; Yang J; Li W
Int J Clin Exp Pathol; 2014; 7(10):6559-66. PubMed ID: 25400734
[TBL] [Abstract][Full Text] [Related]
6. Immunodominant epitope-specific Th1 but not Th17 responses mediate protection against Helicobacter pylori infection following UreB vaccination of BALB/c mice.
Li B; Chen L; Sun H; Yang W; Hu J; He Y; Wei S; Zhao Z; Zhang J; Li H; Zou Q; Wu C
Sci Rep; 2015 Oct; 5():14793. PubMed ID: 26434384
[TBL] [Abstract][Full Text] [Related]
7. Antibody Production and Th1-biased Response Induced by an Epitope Vaccine Composed of Cholera Toxin B Unit and Helicobacter pylori Lpp20 Epitopes.
Li Y; Chen Z; Ye J; Ning L; Luo J; Zhang L; Jiang Y; Xi Y; Ning Y
Helicobacter; 2016 Jun; 21(3):234-48. PubMed ID: 26332255
[TBL] [Abstract][Full Text] [Related]
8. Intranasal CpG-oligodeoxynucleotide is a potent adjuvant of vaccine against Helicobacter pylori, and T helper 1 type response and interferon-gamma correlate with the protection.
Shi T; Liu WZ; Gao F; Shi GY; Xiao SD
Helicobacter; 2005 Feb; 10(1):71-9. PubMed ID: 15691317
[TBL] [Abstract][Full Text] [Related]
9. Th immune response induced by H pylori vaccine with chitosan as adjuvant and its relation to immune protection.
Xie Y; Zhou NJ; Gong YF; Zhou XJ; Chen J; Hu SJ; Lu NH; Hou XH
World J Gastroenterol; 2007 Mar; 13(10):1547-53. PubMed ID: 17461447
[TBL] [Abstract][Full Text] [Related]
10. Helicobacter pylori lipopolysaccharide promotes a Th1 type immune response in immunized mice.
Taylor JM; Ziman ME; Huff JL; Moroski NM; Vajdy M; Solnick JV
Vaccine; 2006 Jun; 24(23):4987-94. PubMed ID: 16621176
[TBL] [Abstract][Full Text] [Related]
11. Intranasal immunization with immunodominant epitope peptides derived from HpaA conjugated with CpG adjuvant protected mice against Helicobacter pylori infection.
Yang WC; Sun HW; Sun HQ; Yuan HM; Li B; Li HB; Hu J; Yang Y; Zou QM; Guo H; Wu C; Chen L
Vaccine; 2018 Oct; 36(42):6301-6306. PubMed ID: 30217524
[TBL] [Abstract][Full Text] [Related]
12. Effects of a Th1- versus a Th2-biased immune response in protection against Helicobacter pylori challenge in mice.
Taylor JM; Ziman ME; Canfield DR; Vajdy M; Solnick JV
Microb Pathog; 2008 Jan; 44(1):20-7. PubMed ID: 17683897
[TBL] [Abstract][Full Text] [Related]
13. Systemic immunization with unadjuvanted whole Helicobacter pylori protects mice against heterologous challenge.
Harbour SN; Every AL; Edwards S; Sutton P
Helicobacter; 2008 Dec; 13(6):494-9. PubMed ID: 19166414
[TBL] [Abstract][Full Text] [Related]
14. Development and evaluation of a DNA vaccine based on Helicobacter pylori urease B: failure to prevent experimental infection in the mouse model.
Zavala-Spinetti L; Breslin MB; Correa H; Bégué RE
Helicobacter; 2006 Dec; 11(6):517-22. PubMed ID: 17083372
[TBL] [Abstract][Full Text] [Related]
15. The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization.
Akhiani AA; Stensson A; Schön K; Lycke N
Scand J Immunol; 2006 Feb; 63(2):97-105. PubMed ID: 16476008
[TBL] [Abstract][Full Text] [Related]
16. Mucosal immune responses are related to reduction of bacterial colonization in the stomach after therapeutic Helicobacter pylori immunization in mice.
Nyström J; Raghavan S; Svennerholm AM
Microbes Infect; 2006 Feb; 8(2):442-9. PubMed ID: 16243563
[TBL] [Abstract][Full Text] [Related]
17. Systemic Th1 immunization of mice against Helicobacter pylori infection with CpG oligodeoxynucleotides as adjuvants does not protect from infection but enhances gastritis.
Sommer F; Wilken H; Faller G; Lohoff M
Infect Immun; 2004 Feb; 72(2):1029-35. PubMed ID: 14742550
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Protection Against
Guo L; Hong D; Wang S; Zhang F; Tang F; Wu T; Chu Y; Liu H; He M; Yang H; Yin R; Liu K
Front Immunol; 2019; 10():1185. PubMed ID: 31191547
[TBL] [Abstract][Full Text] [Related]
19. Systemic immunization with urease protects mice against Helicobacter pylori infection.
Guy B; Hessler C; Fourage S; Haensler J; Vialon-Lafay E; Rokbi B; Millet MJ
Vaccine; 1998 May; 16(8):850-6. PubMed ID: 9627943
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a new tumor necrosis factor-alpha-inducing membrane protein of Helicobacter pylori as a prophylactic vaccine antigen.
Inoue K; Shiota S; Yamada K; Gotoh K; Suganuma M; Fujioka T; Ahmed K; Iha H; Nishizono A
Helicobacter; 2009 Oct; 14(5):135-43. PubMed ID: 19751439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
